A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 1 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in Oncology MOST POPULAR The future of research: meet three of our scientists working on... December 13, 2022 2021/22 in review: Charity looks to the future with ambitious new... July 21, 2022 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Seven Extra Years July 2, 2022 Load more HOT NEWS How the National Cancer Act Has Made a Difference in Cancer... Study Offers Insights on Health Problems among AYA Cancer Survivors Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord...
